Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CGP 35269

Drug Profile

CGP 35269

Alternative Names: CGP35269; IFNα B/D; Interferon-alpha B/D hybrid; Interferon-alpha-1/alpha-8 hybrid; Recombinant human interferon-alpha B/D hybrid; rHu INF-alpha B/D hybrid

Latest Information Update: 26 Aug 2002

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Class Interferons
  • Mechanism of Action Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Hepatitis B; HIV infections; Viral haemorrhagic fevers

Most Recent Events

  • 29 Dec 1998 Preclinical development for Viral haemorrhagic fevers in USA (Unknown route)
  • 29 Dec 1998 A study of viral haemorrhagic fever has been added to the pharmacodynamics section
  • 26 Feb 1997 Phase-II clinical trials for Hepatitis B in Belgium (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top